Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene results in CF. The most common mutation, ΔF508-CFTR, is a temperature-sensitive, trafficking mutant with reduced chloride transport and exaggerated immune response. The ΔF508-CFTR is misfolded, ubiquitinated, and prematurely degraded by proteasome mediated- degradation. We recently demonstrated that selective inhibition of proteasomal pathway by the FDA approved drug PS-341 (pyrazylcarbonyl-Phe-Leuboronate, a.k.a. Velcade or bortezomib) ameliorates the inflammatory pathophysiology of CF cells. This proteasomal drug is an extremely potent, stable, reversible and selective inhibitor of chymotryptic threonine protease-activity. The apprehension in considering the proteasome as a therapeutic target is that proteasome inhibitors may affect proteostasis and consecutive processes. The affect on multiple processes can be mitigated by nanoparticle mediated PS-341 lung-delivery resulting in favorable outcome observed in this study. RESULTS: To overcome this challenge, we developed a nano-based approach that uses drug loaded biodegradable nanoparticle (PLGA-PEGPS-341) to provide controlled and sustained drug delivery. The in vitro release kinetics of drug from nanoparticle was quantified by proteasomal activity assay from days 1-7 that showed slow drug release from day 2-7 with maximum inhibition at day 7. For in vivo release kinetics and biodistribution, these drug-loaded nanoparticles were fluorescently labeled, and administered to C57BL6 mice by intranasal route. Whole-body optical imaging of the treated live animals demonstrates efficient delivery of particles to murine lungs, 24 hrs post treatment, followed by biodegradation and release over time, day 1-11. The efficacy of drug release in CF mice (Cftr-/-) lungs was determined by quantifying the changes in proteasomal activity (~2 fold decrease) and ability to rescue the Pseudomonas aeruginosa LPS (Pa-LPS) induced inflammation, which demonstrates the rescue of CF lung disease in murine model. CONCLUSION: We have developed a novel drug delivery system to provide sustained delivery of CF "correctors" and "anti-inflammatories" to the lungs. Moreover, we demonstrate here the therapeutic efficacy of nano-based proteostasis-modulator to rescue Pa-LPS induced CF lung disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495 · cited 2×
“We and others have recently reported that selective inhibition of proteasome activity helps in rescue of misfolded or partially folded protein by induction of folding machinery [8,9,16-19] and it is not possible to traffic or rescue the misfolded protein by inhibiting its ubiquitination due to presence of redundant ub…”
BackgroundThe uptake and intracellular fate of PLGA nanoparticles in epithelial cells
Cartiera, M. S., Johnson, K. M., Rajendran, V., Caplan, M. J., & Saltzman, W. M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.057 · Cited by 412 · cited 1×
“These nanoparticulate systems are rapidly endocytosed by cells followed by release of their therapeutic payload by both passive diffusion and slow matrix degradation [12,13].”
BackgroundNanodelivery in airway diseases: Challenges and therapeutic applications
Roy, I., & Vij, N. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.07.001 · Cited by 137 · cited 3×
“The major challenge in delivery and therapeutic efficacy of nano-delivery systems in chronic obstructive airway conditions is severe inflammation and mucous hypersecretion [14,28].”
BackgroundSelf-citation
Cited by
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
A holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers
Salmaso, S., & Caliceti, P. (2013) · Journal of Drug Delivery · doi:10.1155/2013/374252 · Cited by 340
Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases
Vij, N., Min, T., Bodas, M., Gorde, A., & Roy, I. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.06.008 · Cited by 85
Self-citationNano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential
Vij, N. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.597381 · Cited by 60
“Similarly in CF, correction of misfolded cystic fibrosis transmembrane conductance regulator requires targeted drug/gene delivery as recently shown using a novel nanosystem capable of overriding airway defense and providing sustained drug release [14].”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Vij, N., Min, T., Marasigan, R., Belcher, C. N., Mazur, S., Ding, H., Yong, K.-T., & Roy, I.
- Venue
- Journal of Nanobiotechnology
- Published
- 2010
- Volume
- 8
- Issue
- 1
- Pages
- 22
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W2093741622
- Cited by
- 126
- References
- 3
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.